Axsome Therapeutics
AXSM
129.36
-6.32
-4.66%
Axsome Therapeutics
US · AXSM
#1533 by market cap
Listed 2015
129.36
-6.32
-4.66%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
D-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-08.
Analyst consensus 17 analysts
Buy
Avg price target 263.94 +104.0%
Price target rangecurrent 129.36
Low220.00
Avg263.94
High310.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | Morgan Stanley | -- | Hold | 223.00 |
| 2026-11-09 | H.C. Wainwright | -- | Buy | 290.00 |
| 2026-11-04 | Mizuho Securities | -- | Buy | 272.00 |
| 2026-11-03 | Wells Fargo | -- | Buy | 256.00 |
| 2026-11-03 | UBS | -- | Buy | 239.00 |
| 2026-11-03 | Baird | -- | Buy | 220.00 |
| 2026-11-03 | Morgan Stanley | -- | Hold | 249.00 |
| 2026-11-03 | Deutsche Bank | -- | Buy | 245.00 |
| 2026-11-03 | Guggenheim | -- | Buy | 250.00 |
| 2026-11-02 | Cantor Fitzgerald | -- | Buy | 272.00 |
| 2026-11-02 | UBS | -- | Buy | 239.00 |
| 2026-11-02 | Piper Sandler | -- | Buy | 235.00 |
| 2026-11-02 | BofA Securities | -- | Buy | 264.00 |
| 2026-11-02 | Morgan Stanley | -- | Hold | 249.00 |
| 2026-11-02 | Jefferies | -- | Buy | 305.00 |
| 2026-11-02 | BMO Capital | -- | Buy | 310.00 |
| 2026-11-02 | RBC Capital | -- | Buy | 273.00 |
| 2026-10-29 | Mizuho Securities | -- | Buy | 284.00 |
| 2026-10-29 | Oppenheimer | -- | Buy | 280.00 |
| 2026-10-26 | Piper Sandler | -- | Buy | 238.00 |
| 2026-10-15 | Needham | -- | Buy | 268.00 |
| 2026-10-14 | RBC Capital | -- | Buy | 295.00 |
| 2026-10-12 | BMO Capital | -- | Buy | 310.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 276.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 295.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-08 | Morgan Stanley | Buy → Hold | 204.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | -- | ±13.38% | -5.83% (in line) |
| 2026/Q2 | 2026-08-10 | -- | ±8.79% | +3.83% (in line) |
| 2026/Q1 | 2026-05-04 | -- | ±5.99% | +8.31% (beat) |
| 2025/Q4 | 2026-02-23 | -- | ±7.60% | -4.88% (in line) |
| 2025/Q3 | 2025-11-03 | -- | ±7.47% | +0.56% (in line) |
| 2025/Q2 | 2025-08-04 | -- | ±8.91% | +3.42% (in line) |
| 2025/Q1 | 2025-05-05 | -- | ±9.42% | +3.81% (in line) |
| 2024/Q4 | 2025-02-18 | -- | ±7.68% | -2.33% (in line) |
| 2024/Q3 | 2024-11-12 | -- | ±9.77% | +9.35% (in line) |
| 2024/Q2 | 2024-08-05 | -- | ±11.19% | -1.43% (in line) |
| 2024/Q1 | 2024-05-06 | -- | ±9.37% | +1.52% (in line) |
| 2023/Q4 | 2024-02-20 | -- | ±12.67% | -12.57% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Axsome Therapeutics discussion 0 comments